At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 180 enrolled
Drug / intervention
Chamomile (Matricaria recutita)drug
Likely dose
Chamomile (Matricaria recutita) 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD)
In Brief
A Phase 3 clinical trial evaluating Chamomile (Matricaria recutita) for Generalized Anxiety Disorder. Completed, enrolled 180 participants across 1 site.
Detailed Summary
Prior research has shown that chamomile may be an effective, short-term anti-anxiety treatment. This study will examine the initial and long-term benefits of chamomile extract therapy for the prevention of recurrent anxiety disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Anxiety Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedFeb 2010
Primary CompletionJun 2015
TodayJul 2026
First PostedFeb 22, 2010
Enrollment StartFeb 1, 2010
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 16.4 years ago
Interventions
Chamomile (Matricaria recutita)drug
500 mg 3 times daily